Background. Infections with human parechoviruses (HPeVs) are associated with a wide range of clinical presentations in children, ranging from mild or asymptomatic infections to severe sepsis-like presentations or meningoencephalitis.
Human parechoviruses (HPeVs) are small, nonenveloped RNA viruses within the Parechovirus genus of the Picornaviridae family. In the late 1990s, HPeVs were identified as genetically distinct from enteroviruses and reclassified into a separate genus. To date, 16 genotypes of HPeV have been identified. HPeV infections typically target young children <2 years old and are often asymptomatic [1] . By 2 years of age, >90% of children have antibodies to at least 1 HPeV type [2, 3] .
HPeV type 3 (HPeV-3) was first identified in Japan in a 1-year-old child with transient paralysis, fever, and diarrhea [4] and, shortly afterward, was recovered from nasopharyngeal aspirates (NPAs) of neonates with suspected sepsis in Canada [5] . HPeV-3 is associated with central nervous system infection, encephalitis, and meningitis, and a sepsis-like syndrome, particularly affecting young infants [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . The severe systemic disease associated with HPeV-3 infection may be due to lower rates of specific antibodies in adults [22] , particularly in women of childbearing age [4] , compared with almost universal seropositivity against HPeV type 1 [2, 3] . The lower seroprevalence of HPeV-3 in adults may be a direct consequence of its more recent emergence globally [23] . Alternatively, HPeV-3 may be intrinsically more virulent with greater neurotropism and greater ability to disseminate [24] .
We describe the clinical features of 118 infants admitted to hospital in New South Wales (NSW), Australia, with severe HPeV-3 infection during an outbreak in 2013-2014.
METHODS
We performed a retrospective review of infants <12 months with proven HPeV infection admitted to 3 tertiary children's hospitals in NSW (The Children's Hospital at Westmead [CHW] , Sydney Children's Hospital [SCH] , and The John Hunter Children's Hospital [JHCH] in Newcastle) or to the pediatric units of 2 regional hospitals (Orange Base Hospital and Wollongong Hospital) between 1 October 2013 through 31 January 2014. Suspected cases of HPeV infection were identified by pediatricians at each hospital. Infants presenting with fever and sepsis-like illness (≥2 of tachycardia, tachypnea, rash, irritability, hepatitis, diarrhea, encephalitis) had samples tested for HPeV RNA by reverse transcription polymerase chain reaction (RT-PCR). Infection was proven if HPeV RNA was detected in at least 1 of cerebrospinal fluid (CSF), stool, rectal swab, NPA, throat swab, urine, or whole blood.
Laboratory testing at the Victorian Infectious Diseases Reference Laboratory (VIDRL) used primers targeting the highly conserved 5′ untranslated region, allowing detection of all known HPeV types as previously described [25] . The accuracy of these primers has been verified by in-house validation and subsequent genotyping of positive samples. Primer and probe sequence details are available on request. Amplification by a seminested PCR described by Nix et al [26] and sequencing of the 704-bp fragment of the highly variable VP1 region allowed identification of specific genotypes. At least 20% of positive patients were selected for genotyping. Phylogenetic analysis was carried out using BioEdit version 7.0.1 [27] with Kimura 2-parameter model used as the default model of evolution, followed by neighbor joining to create the final tree.
Routine bacteriology and virology tests were carried out at each hospital according to local practice. Testing for respiratory viruses on NPAs and for enteric viruses on stool samples was carried out using commercially available immunofluorescence, antigen detection, and multiplex PCR assays (Supplementary Data 1). Investigators reviewed the medical records of children with proven HPeV infection. Descriptive analyses of demographic, clinical, and laboratory characteristics were carried out using GraphPad Prism and Microsoft Excel. Ethical approval was granted by the Sydney Children's Hospitals Network Human Research Ethics Committee (LNR/13/SCHN/454).
RESULTS
We identified 118 infants with HPeV infection (CHW, 42; SCH, 37; JHCH, 29; Wollongong, 6; Orange, 4). The epidemic occurred during late spring and early summer (Figure 1 ). Sixtyfive infants were male (55%). Median age at onset of symptoms was 39 days (range, 4 days to 9.5 months), with 75% of infants ≤60 days. Thirty children (25%) were admitted to an intensive care unit (ICU). The median age at onset of symptoms of children admitted to ICU was 16.5 days (range, 4-78 days), which was significantly younger (unpaired t test P = .0004) than children not admitted to ICU (median age, 43.5 days; range, 6 days to 9.5 months).
Complete clinical data were available for 115 patients (Table 1) . Fever was defined as temperature >38°C in hospital or history of "fever" at home. Seventy-five children (65%) had documented fever ≥39°C. For the 110 children with data, the duration of fever was 1-9 days with a median of 3 days. Maximum recorded heart and respiratory rates were 240 beats/ minute and 95 respirations/minute, respectively. Unusual presentations in some infants are described in Table 2 . Striking clinical features noted were abdominal distention, poor perfusion, peripheral or generalized edema, respiratory distress, and rash ( Figure 2 ). Four infants had clinical seizures with abnormal electroencephalography.
The median duration of admission was 4 days (range, 2-13 days). The median duration of ICU stay was 4 days (range, 1-13 days). At least 1 fluid bolus (for tachycardia and/or poor perfusion) was administered to 73 of 116 infants (63%); 12 received 40-70 mL/kg over several days. Six infants received blood products (albumin, 3; fresh frozen plasma, 2; platelets, 1). Five infants required mechanical ventilation, including 1 with heart failure from congenital heart disease; 2 also received inotropes. An additional 9 infants received continuous positive airway pressure (CPAP) and 15 received high-or low-flow oxygen. Analgesia was required (for irritability or distress) by 107 of 115 infants (93%); 8 received intravenous or oral morphine, and an additional 8 received intravenous paracetamol. Empiric intravenous antibiotics and intravenous acyclovir were administered to 115 of 117 (98%) and 30 of 117 (26%) of children, respectively, for at least 24 hours. Table 3 outlines the number of clinical samples positive for HPeV RNA. Thirty CSF samples were not tested for HPeV when other positive samples were available. Stool samples were prioritized for testing by NSW Public Health due to greater sensitivity for detection of HPeV and high assay cost. Negative HPeV PCR results were found in 4 of 79 (5%) CSF samples, 1 of 69 stool samples, and 1 of 12 NPA samples. Sequencing of the VP1 gene confirmed HPeV-3 in all 27 selected representative samples tested (including 1 parent-child pair).
CSF white cell counts (WCCs) were available for 104 infants. WCCs were corrected for presence of red blood cells (RBCs) in traumatic lumbar punctures (2 WCCs for every 1000 RBCs/µL) /L) and 10% (12/118) had thrombocytopenia (platelets <150 × 10 9 /L). Serum C-reactive protein (CRP) was >10 mg/L in 34 of 110 (31%) subjects. Only 6 children (5%) had serum CRP levels >30 mg/L (maximum 58 mg/L). Hepatitis, defined as serum aminotransferase levels >2 times the upper limit of normal (aspartate aminotransferase or alanine aminotransferase >100 U/L) was detected in 27 of 83 children measured. Deranged coagulation profiles (activated partial thromboplastin time ≥50 seconds or international normalized ratio of prothrombin time ≥1.5) were seen in 17 of 31 subjects tested.
All infants had blood cultures performed on admission. Four grew presumed contaminants (coagulase-negative staphylococci, 2; "diphtheroid," 1; Chryseobacterium species, 1). All others were sterile. One hundred fourteen children had urine cultures collected; 9 with possible or probable urinary tract infections ( Ultrasound scans performed in 17 children were noncontributory. Brain magnetic resonance imaging (MRI) was performed in 11 infants aged <60 days; 4 with seizures, 1 for an unrelated congenital malformation, and the rest for extreme irritability. Four (3 with seizures) had widespread diffusion restriction in the white matter and thalami (Figure 3) . One of them received intravenous methylprednisolone 30 mg/kg/day for 3 days for presumed cerebral vasculitis; repeat imaging after 1 week demonstrated significant resolution of diffusion restriction. A further 3 children had patchy T2-weighted subcortical white matter changes. One of these children also had a repeat MRI after 2 weeks that showed resolution of changes.
Our series included 1 pair of twins and 1 set of cousins. Another pair of twins with onset of symptoms 2 days apart had HPeV infection confirmed in 1 twin and a clinical diagnosis made in the other. HPeV RNA was detected in a throat swab from the 40-year-old father of a neonate admitted to ICU. The father's low-grade fever and severe generalized myalgia started 1 day after his daughter's illness. A history of close family members with symptoms of respiratory or gastrointestinal tract infection was not routinely sought but was recorded in 39% of cases. We did not identify any nosocomial HPeV infections.
All infants were well at discharge. One neonate was readmitted 2 weeks after discharge with enterovirus meningitis (CSF WCC, 105 including 95 monocytes; enterovirus RNA detected by RT-PCR in stool, NPA, and CSF) but recovered and was doing well at follow-up aged 4 months. Pediatricians have reported 4 infants with abnormal gross motor development or limb tone at 3-6 months of age. All other infants reviewed by a pediatrician between 2 and 12 months of age are neurologically normal.
DISCUSSION
To our knowledge, this is the largest recorded outbreak of HPeV-3 infection in infants and the first in Australia. From the 118 infants in our cohort, genotyping was performed on 26 patients and 1 parent, all of which were confirmed to be HPeV-3. An additional 7 cases had clinical and epidemiological evidence of HPeV infection, but no laboratory testing, and have not been included. During the study period, many clinically similar cases presented to other hospitals in NSW and elsewhere in Australia, but are not included. All HPeV samples genotyped at VIDRL during this epidemic (14 of 60 other NSW patients and 10 patients from other Australian states) were confirmed to be HPeV-3 (G. Papadakis, personal communication). All isolates were closely related (Figure 4) . Given the clustering of cases in time and the similarity of presentations, we assume that all cases of HPeV infection were due to HPeV-3.
Previous case reports and small case series of HPeV-3 infection reported similar severe infections in neonates and young infants. Our series is the largest reported to date with complete clinical data and includes infants up to 9.5 months of age. The proportion of HPeV-3 infections occurring in infants >2 months (25%) contradicts previous reports that HPeV-3 infection occurs nearly exclusively in infants <3 months of age [5, 6, 9-13, 15, 19, 20] . This may be due to greater awareness by pediatricians and the wider community due to Public Health alerts and improved testing of suspected cases.
The NSW outbreak spanned 4 months in late spring to early summer, peaking in the last week of November and first 2 weeks [6, 14, 30] , whereas overall HPeV infections tend to occur in late summer and autumn months [1, 7, 12, 16, 18, 19] . We assume the virus was newly introduced into the community in the spring of 2013. We speculate that the youngest infants became the most severely affected due to low maternal antibody levels, whereas older children and adults probably experienced milder or even asymptomatic infection due to immune maturity and possibly some cross-protection from previous exposure to other HPeV types. Due to lack of routine testing, we are unable to comment on the full range of clinical presentations in the wider community, of less-ill infants, and of older children and adults. Public health efforts heightened clinician awareness and some patients did not require hospital admission. A few weeks after the NSW epidemic had waned, clusters of similar cases presented in several other Australian states and in New Zealand [31] .
A recent report from Japan of an outbreak of epidemic myalgia in adults associated with HPeV-3 has established that adults can also experience symptomatic HPeV-3 infection [32] , providing further evidence that some adults may not have had HPeV-3 infection in childhood. We proved symptomatic HPeV infection in the father of 1 of the infants in our series. Although we did not routinely test parents of infected children, a large number of infants had unwell family members, and many parents described "flu-like" symptoms.
Our series has a less marked male preponderance (55%) than previously reported [7, 10, 13, 16] . Clinical features in our cohort are similar to those previously described [16, 19, 21] , although we found a lower rate of seizures. A high proportion of our infants had the triad of fever, irritability, and rash: "red, hot, angry babies," as reported by others [7, 10, 16] . These features allowed rapid and accurate identification of infected infants by pediatricians during the outbreak. The majority of the children in our series displayed a widespread, macular, and often erythrodermic rash. We saw a plantar-palmar rash, described by other authors [9, 13] , in only 3 infants. The irritability observed in almost all children in our series was often perceived by parents and clinicians to be due to pain, prompting the use of regular and significant analgesia.
Despite almost universal presence of high fevers, as well as other nonspecific features of suspected sepsis, we did not find significantly raised inflammatory markers, with 94% of infants having serum CRP levels ≤30 mg/L. Significant abdominal distension, previously described in young infants with HPeV-3 infection [9, 33] , was seen in 13% of our series, all in infants aged <3 months. Yuzurihara et al described 2 neonates with a hemophagocytic lymphohistiocytosis (HLH)-like condition [9] , treated with corticosteroids and other immunomodulators. In our series, 2 neonates presented with clinical and laboratory features suggestive of neonatal HLH [34] or Kawasaki disease; 1 defervesced following intravenous immunoglobulin and the other, who also had hepatitis and coagulopathy, recovered without immunomodulatory treatment. HPeV-3 has previously been reported as a cause of hepatitis coagulopathy syndrome in neonates with a similarly short clinical course [20] . These cases suggest that HPeV-3 is capable of inducing significant immune activation in neonates with subsequent tissue damage.
Absence of CSF pleocytosis, which we found in 96% of cases, has been described previously [8, 10, 16, 17, 19, 21] . The brain MRI changes we found in selected patients, showing white matter and thalamic diffusion restriction, have been described previously in neonatal HPeV-3 encephalitis [13, 17, 19, 20] . Significant white matter abnormalities resolved partially or completely after 1-2 weeks in 2 of our patients, 1 following high-dose methylprednisolone treatment; the other had received intravenous hydrocortisone as part of hemodynamic support measures. Two neonates in our series had normal neurological examination and CSF microscopy despite extensive white matter abnormalities on MRI, a finding reported in 1 of 10 neonates in a Dutch series of neonatal HPeV-3 encephalitis [17] , suggesting that such abnormalities may be more common in the acute stage than identified. Normal neurological examination and absent CSF pleocytosis probably deter pediatricians from performing neuroimaging studies in the majority of children [8] .
The median duration of hospital admission in our series (4 days) is similar to that reported in a US study [16] , but shorter than that reported by others (mean of 7 or median of 8 days) [7, 13] . Treatment of HPeV infection is primarily supportive; however, because the clinical presentation mimics bacterial sepsis or HSV infection, almost all children are treated empirically with intravenous antibiotics and many with intravenous acyclovir. In this cohort, 25% of infants were admitted to ICU, although <10% required intensive support (inotropes, mechanical ventilation, or CPAP). During the peak of the outbreak, this put significant strain on acute retrieval services and intensive care facilities. The majority of infants were admitted to ICU due to their initial severe presentations and inability to rapidly diagnose HPeV infection. Addition of HPeV RT-PCR assay to the enterovirus RT-PCR assay for pediatric CSF or stool samples, particularly from infants aged <3 months, might reduce length of hospital admissions and empiric intravenous antibiotic treatment. All infants in our series were well at discharge. Some small series have described significant long-term neurodevelopmental morbidity in up to 40% of neonatal HPeV-3 infection [17, 19] ; however, there may be selection and reporting bias, if only severely affected infants are tested for infection. Our large series has the advantage of including infants with milder illness only briefly admitted to hospital. Four infants have been noted to have abnormalities of gross motor development or limb tone at 3-6 months of age; all other infants aged 2-12 months who have had clinical review by a pediatrician are doing well and achieving normal developmental milestones.
CONCLUSIONS
We report the largest series of HPeV-3 infection in infants, and the first outbreak in Australia, spanning 4 months in late spring to early summer of 2013-2014. The majority of infants were aged <2 months, suggesting recent introduction of the virus into the population. Infants presented with a severe sepsis-like syndrome, with 25% requiring ICU admission. The availability of HPeV RT-PCR assays to test pediatric CSF or stool samples may help to reduce length of hospital admissions and unnecessary use of empiric antibiotics during such outbreaks. All infants in our series recovered from the acute infection without significant complications related to HPeV-3. Focused longitudinal follow-up and cognitive evaluation are necessary to document long-term consequences of HPeV infection in infancy. Such follow-up has been initiated in most of the children described in this report by treating pediatricians, as well as part of an ongoing research project.
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